Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24573762 | 0.74 | HSD17B1 (0.42) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL13628703 | 0.73 | MEN1 (0.34) | MEN1KMT2ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL24573403 | 0.72 | ALDH1A1 (0.41) | MAPTHSD17B10ALOX12KMT2AALOX15 | |
| SCHEMBL24573393 | 0.72 | HSD17B1 (0.42) | MAPTMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL24573404 | 0.70 | ALDH1A1 (0.30) | HSD17B10KDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8716896 | 0.70 | CYP2A6 (0.45) | MAPTMEN1KMT2AALOX15KDM4E | |
| SCHEMBL10159988 | 0.70 | — | — | |
| SCHEMBL14074871 | 0.69 | ALDH1A1 (0.33) | ALDH1A1HPGD | |
| SCHEMBL197157 | 0.68 | SNCA (0.50) | MAPTHSD17B10ALOX12MEN1KMT2A | |
| SCHEMBL15422384 | 0.68 | MAPT (0.45) | MAPTHSD17B10ALOX12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| WO-2020161375-A2 | METHOD FOR OBTAINING GLYCOCONJUGATES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-08-13 | — | — | WO | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1783124-A1 | 2-PHENYLTHIOPHENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| CN-1771050-A | macrocyclic inhibitors of hepatitis c serine protease | ENANTA PHARM INC (US) | 2006-05-10 | — | — | CN | disclosed |
| US-20050267054-A1 | Antibacterial compounds with improved pharmacokinetic profiles | CLARK RICHARD F | 2005-12-01 | — | — | US | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1501845-A1 | ANTIBACTERIAL COMPOUNDS WITH IMPROVED PHARMACOKINETIC PROFILES | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040033970-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABBOTT LABORATORIES | 2004-02-19 | — | — | US | disclosed |
| WO-2003093288-A1 | ANTIBACTERIAL COMPOUNDS WITH IMPROVED PHARMACOKINETIC PROFILES | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030207820-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABBOTT LABORATORIES | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267054-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABCB11, SLC10A2, SI | MAPT 4130/4885HSD17B10 731/4885ALOX12 1294/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | MAPT 4214/4885HSD17B10 751/4885ALOX12 2245/4885 |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | MAPT 3889/4885HSD17B10 239/4885ALOX12 487/4885 |
| US-20030207820-A1 | Antibacterial compounds with improved pharmacokinetic profiles | UGT1A1, ABCB11, SLC10A1 | MAPT 4491/4885HSD17B10 690/4885ALOX12 1307/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | MAPT 2826/4885HSD17B10 3869/4885ALOX12 1186/4885 |
| US-20040033970-A1 | Antibacterial compounds with improved pharmacokinetic profiles | UGT1A1, ABCB11, SLC10A1 | MAPT 4491/4885HSD17B10 690/4885ALOX12 1307/4885 |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | MAPT 1064/4885HSD17B10 699/4885ALOX12 169/4885 |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | HDAC6, HHAT, HDAC1 | MAPT 136/4885HSD17B10 373/4885ALOX12 3539/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | MAPT 4280/4885HSD17B10 764/4885ALOX12 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.